asbt

Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM) that can lower glucose in an animal model of type 2 diabetes and demonstrates excellent developability properties.

Maralixibat Chloride (LUM001 chloride), an apical, sodium-dependent, bile acid transport inhibitor, prevents enterohepatic bile acid recirculation.

S 0960 is a dimeric bile acid analog, a specific inhibitor of the sodium-dependent bile salt transporter in the ileum, used in metabolic disease research.

Elobixibat (A 3309) is an inhibitor of the ileal bile acid transporter (IC50: 0.13 nM, 0.53 nM, and 5.8 nM for mouse, human, and canine IBAT). Elobixibat can be used in studies about chronic idiopathic constipation.

SC-435 is an ileal apical sodium co-dependent bile acid transporter (ASBT). SC-435 inhibits plasma cholesterol.

264W94 is a robust inhibitor of the ileal bile acid transporter (IBAT) and a novel agent for reducing cholesterol levels. It exhibits CYP7A1 induction and demonstrates significant antilipemic activity.

Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.

S-8921 is an inhibitor of ileal Na+/bile acid cotransporter.

Volixibat is a highly selective and competitive apical sodium-dependent bile acid transporter inhibitor. Volixibat has the potential for treatment for non-alcoholic steatohepatitis.

Ritivixibat is an ileal bile acid transporter (IBAT) inhibitor and bile acid modulator. It is utilized in research related to cardiovascular diseases, fatty acid metabolism disorders, glucose utilization abnormalities, gastrointestinal conditions, and liver diseases.

Elobixibat hydrate, a potent inhibitor of the ileal bile acid transporter (IBAT), exhibits IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human, mouse, and canine IBAT, respectively. It is utilized in the research of chronic idiopathic constipation (CIC).

(S)-Elobixibat is the S-isomer of Elobixibat. It is an orally active inhibitor of Apical Sodium-Dependent Bile (IBAT) and can reduce LDL cholesterol, increase serum GLP-1, and promote colonic motility. This compound shows potential for treating metabolic syndrome and can be studied for constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.

S1647 is a dual inhibitor targeting both ASBT and SOAT. It is utilized in research focused on intrahepatic cholestasis, cholestatic pruritus, and constipation.